Citations: Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes

Views

CrossRef citations to date

Altmetric

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (4)

Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, I. Hayashi, M. Tsugawa, H. Yokoyama, H. Yoshii, K. Komiyama, T. Mita, T. Shimizu, T. Yamamoto, S. Kawashima, T. Nakamura, S. Kamei, T. Kinoshita, M. Shimoda, K. Maeda, K. Kosugi, H. Yoshii, H. Ishida, T. Osonoi, M. Saito, A. Tamazawa, S. Sumitani, N. Fujiki, Y. Fujita, S. Shimizu, Y. Umayahara, K. Kato, Y. Irie, R. Kataoka, T. Yasuda, Y. Kiyohara, M. Ohashi, K. Ryomoto, Y. Takahi, Y. Fujishima, Y. Fujita, A. Fukuhara, K. Fukui, Y. Hosokawa, A. Imagawa, H. Iwahashi, K. Mukai, N. Katakami, T. Katsura, D. Kawamori, T. Kimura, S. Kobayashi, J. Kozawa, F. Kubo, N. Maeda, T. Matsuoka, K. Miyashita, S. Nakata, H. Ninomiya, H. Nishizawa, Y. Okuno, M. Otsuki, F. Sakamoto, S. Sasaki, I. Sato, N. Shimo, I. Shimomura, M. Takahara, T. Takano, A. Tokunaga, S. Uno, M. Yamaoka, S. Yoneda, K. Ohtoshi, T. Shiraiwa, M. Hajime, K. Koikawa, F. Kuno, A. Kurozumi, K. Matsushita, M. Narisawa, K. Tanaka, K. Sugai, Y. Okada & K. Torimoto. (2021) The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy 12:9, pages 2499-2515.
Crossref

Laura K. Triantafylidis, Chelsea E. HawleyChristopher Fagbote, Jiahua Li, Nicole Genovese & Julie M. Paik. (2019) A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease. Journal of Pharmacy Practice 34:3, pages 428-437.
Crossref

Vivencio Barrios & Carlos Escobar. (2021) Canagliflozin: metabolic, cardiovascular and renal protection. Future Cardiology 17:3, pages 443-458.
Crossref

Hitoshi Ishii, Hiroki Nakajima, Nozomu Kamei, Tetsuji Niiya, Toru Hiyoshi, Yuko Hiramori, Shigeyuki Ohtsu, Takashi Noto & Dai Shimono. (2020) Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study). Diabetes Therapy 11:12, pages 2959-2977.
Crossref

Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes

Articles from other publishers (4)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes

Citations (4)

Articles from other publishers (4)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date